Applications of 1-Methylpiperidine-2-Carboxylic Acid Hydrochloride in Industrial Manufacturing

1-Methylpiperidine-2-Carboxylic Acid Hydrochloride serves as a reliable specialty intermediate with established application records across key segments of the pharmaceutical and fine chemical sectors. By maintaining strict manufacturing and supply chain controls, we ensure the product supports demanding process needs for efficiency, compliance, and product quality at scale.

1. Active Pharmaceutical Ingredient (API) Intermediate for Antiviral Small Molecules

This material is directly incorporated as a chiral building block in multi-step synthesis pathways for prominent antiviral APIs, where its stereochemistry and reactivity enable precise formation of substituted piperidine motifs within the drug’s backbone. Process chemists value the hydrochloride salt form for its improved solubility and dosing accuracy during mid-stream reaction phases, especially in continuous flow and batch hydrogenation sequences.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• U.S. FDA 21 CFR Part 210/211
• EP, USP, and JP relevant monographs for intermediates
• Controlled residual solvent monitoring per ICH Q3C

Typical usage ratio

• 0.12–0.33 molar equivalents per batch, typically proportional to target API core yield and desired throughput; chemists optimize ratio based on on-site pilot validation

Downstream process integration

• Introduced after initial piperidine ring formation but before late-stage N-alkylation; usually charged in aqueous or mixed solvent systems during amide coupling or reductive amination

Final product types

• Finished antiviral drugs in tablet, capsule, or injectable presentation, e.g. protease inhibitor classes
• GMP-active APIs for global pharmaceutical supply

2. Precursor in Custom Chiral Ligand Synthesis for Asymmetric Catalysis

The compound plays a specialized role in developing advanced chiral ligands required for enantioselective catalysts. Custom ligand manufacturers utilize its defined stereochemistry to build nitrogen heterocyclic frameworks, essential for the metal binding properties of high-performance catalyst families. Direct addition into ligand library formation minimizes byproduct contamination and facilitates batch scale-up.

Industry compliance standards

• ISO 9001:2015 for fine chemical production
• REACH (EC 1907/2006) registration for intermediates
• Chemical Inventory Listing: TSCA (US), EINECS (EU), ENCS (Japan)

Typical usage ratio

• 10–30% weight/weight basis relative to total ligand synthesis batch; ratio fine-tuned for specific ligand geometry and target scalability

Downstream process integration

• Fed into the nitrogeneous backbone assembly step, ahead of metal insertion and ligand purification; timing of addition is synchronized with alkylation or protection group steps

Final product types

• Chiral ligands for use in industrial hydrogenation, hydroformylation, and C-C cross-coupling catalysis
• Referenced standards for pharma and agrochemical synthesis

3. Intermediate in CNS Drug Development Pathways

Medicinal chemists adopt this compound in the modular synthesis of novel central nervous system active candidates, especially where N-methyl piperidine structures impart improved pharmacokinetic or receptor affinity characteristics. Analytical QC teams benefit from its high salt purity during route scouting as it reliably maintains batch-to-batch chiral consistency, reducing purification steps downstream.

Industry compliance standards

• GMP Part II for APIs/intermediates (EU)
• ICH Q11 Development and Manufacture of Drug Substances
• Pharmaceutical Environmental Risk Assessment (ERA) as locally required

Typical usage ratio

• 0.25–0.40 molar equivalents per synthetic route; actual figure defined by CNS drug scaffold and structure–activity relationship mapping

Downstream process integration

• Added at the heterocycle elaboration stage before N-functionalization in the CNS-active candidate assembly; serves as a coupling partner or aminating agent

Final product types

• Pilot-scale CNS-active small molecules
• Active pharmaceutical ingredient building blocks for anxiolytic, antidepressant, or neuroprotective drugs

4. Fine Chemical Intermediate for Agrochemical Synthesis

This hydrochloride is recognized among agrochemical synthesis chemists as a nitrogenous intermediate tailored for constructing refined ring structures in selective herbicides and plant growth modulators. The product’s salt form supports straightforward handling in closed-system batch and semi-batch reactors, ensuring dosing precision in industrial-scale condensation and alkylation reactions common to this downstream sector.

Industry compliance standards

• ISO 14001 for chemical environmental management
• Certis Europe QA for plant protection intermediates
• REACH Annex VII/VIII documentation for production scale

Typical usage ratio

• 5–15% by weight within targeted condensation or cyclization steps, with process engineers adjusting based on molecule complexity and desired crop protection spectrum

Downstream process integration

• Introduced post-chlorination and prior to side-chain functionalization in the synthesis of selective herbicide or PGR scaffolds

Final product types

• Herbicide active ingredients for cereals and horticulture
• Growth regulators and safeners tailored for high-yield farming